iRhythm Technologies Inc
NASDAQ:IRTC
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
iRhythm Technologies Inc
NASDAQ:IRTC
|
4.8B USD |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
195.6B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
178.9B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
145.2B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
124.8B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
110.6B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
47.2B EUR |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
52.7B USD |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
50.9B USD |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
46.3B USD |
Loading...
|
|
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
38.3B USD |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
iRhythm Technologies Inc
Glance View
In the bustling realm of healthcare technology, where innovation meets necessity, iRhythm Technologies Inc. stands as a pivotal player, translating sophisticated algorithms into tangible, life-saving insights. Founded with the mission to redefine how cardiac care is delivered, iRhythm has pioneered its niche through the Zio platform—a sophisticated, wearable patch that monitors heart rhythms with precision. The Zio's elegant design belies its robust function, offering patients the comfort of continuous monitoring while living their daily lives. It gleans crucial data that is then transmitted to iRhythm's cloud-based platform, where advanced data analytics work tirelessly to think like a seasoned cardiologist, initially parsing through millions of heartbeats to identity potential abnormalities. As healthcare systems worldwide grapple with increasing demands and complexities, iRhythm's business model resonates well with the need for efficiency and effectiveness. The company generates revenue primarily through its patient-centric monitoring services, catering to healthcare providers who seek reliable diagnostic solutions. By billing insurers and healthcare institutions for the analytic results derived from the Zio patch, iRhythm seamlessly integrates into the cardiac care continuum. The blend of cutting-edge technology and strategic partnerships with healthcare providers not only fuels iRhythm's growth but also underscores a broader shift towards personalized and preventive medicine in cardiac care, demonstrating how strategic foresight can align with technical innovation to meet pressing healthcare challenges.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for iRhythm Technologies Inc is 70.4%, which is above its 3-year median of 68.5%.
Over the last 3 years, iRhythm Technologies Inc’s Gross Margin has increased from 66.9% to 70.4%. During this period, it reached a low of 66.9% on Sep 30, 2022 and a high of 70.4% on Sep 30, 2025.